Amgen’s Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II

ORR 28% Versus 37% In Trial Prior To Accelerated Approval

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.